Oil prices rise on talk of Russia sanctions; bouncing off recent lows
Investing.com - JPMorgan has reduced its price target on Bruker (NASDAQ:BRKR) to $50.00 from $60.00 while maintaining an Overweight rating on the stock. The company’s shares, currently trading at $34.72, have experienced a significant decline of 17.44% over the past week, according to InvestingPro data.
The firm noted that Bruker experienced "relative outsized success in 2023 despite choppy end-market conditions" across the industry space, with strong 2024 guidance and 2027 targets suggesting this outperformance should continue. The company’s solid revenue growth of 10.36% and market capitalization of $5.26 billion underscore its market presence.
JPMorgan highlighted Bruker’s strength across regions and end markets, driven by secular trends in proteomics and other ’omics research in what the company describes as the "post-genomic era."
The research firm believes Bruker is "uniquely positioned" with its NMR and timsTOF product portfolio to capitalize on these trends.
JPMorgan expects the ongoing shift in academic funding toward proteomic research will continue to fuel Bruker’s growth, with potential upside to the bottom line from the company’s recent merger and acquisition activities.
In other recent news, Bruker Corporation reported its earnings for the second quarter of 2025, which fell short of analysts’ forecasts. The company announced earnings per share (EPS) of $0.32, missing the expected $0.42 by 23.81%. Revenue was reported at $797.4 million, slightly below the anticipated $812.81 million, marking a 1.9% miss in revenue expectations. These results came alongside soft order numbers that had been anticipated by analysts. Following the earnings announcement, Barclays (LON:BARC) adjusted its price target for Bruker from $46 to $43 but maintained an Overweight rating on the company. The adjustment reflects the recent earnings performance and order softness. These developments indicate a cautious outlook from analysts, despite the maintained rating.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.